InflaRx NV (IFRX)
1.32
-0.12
(-8.33%)
USD |
NASDAQ |
Oct 16, 16:00
1.32
0.00 (0.00%)
After-Hours: 20:00
InflaRx Research and Development Expense (Annual) : 29.03M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 29.03M |
| December 31, 2024 | 38.25M |
| December 31, 2023 | 44.35M |
| December 31, 2022 | 39.37M |
| December 31, 2021 | 42.06M |
| December 31, 2020 | 29.10M |
| Date | Value |
|---|---|
| December 31, 2019 | 49.72M |
| December 31, 2018 | 29.32M |
| December 31, 2017 | 16.18M |
| December 31, 2016 | 5.801M |
| December 31, 2015 | 3.812M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| MediGene AG | -- |
| BioNTech SE | 2.376B |
| Immatics NV | 199.58M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |